NRAS mutation causes a human autoimmune lymphoproliferative syndrome

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• The RAS GTPase subfamily, including KRAS, HRAS, and NRAS, is crucial for cell signaling and frequently mutated in cancer.
• Germline mutations in KRAS and HRAS cause developmental disorders, but NRAS germline mutations were unreported.
• Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of lymphocyte apoptosis, often linked to CD95 pathway defects.

Purpose of the Study:

• To investigate the role of NRAS germline mutations in immune system disorders.
• To identify the molecular mechanisms by which NRAS mutations cause ALPS and cancer predisposition.
• To differentiate the effects of NRAS germline mutations from other RAS oncoproteins.

Main Methods:

• Genetic analysis of patients with ALPS and hematological malignancies.
• In vitro studies to assess the impact of NRAS mutations on cell signaling pathways.
• Evaluation of apoptosis pathways, including CD95-mediated and mitochondrial apoptosis.

Main Results:

• A heterozygous germline Gly13Asp activating mutation in NRAS was identified as a cause of ALPS and hematological malignancy predisposition.
• This NRAS mutation augments RAF/MEK/ERK signaling, reducing BIM levels and impairing mitochondrial apoptosis, independent of CD95.
• NRAS germline mutations lead to selective immune abnormalities without general developmental defects.

Conclusions:

• Germline activating NRAS mutations cause ALPS and cancer predisposition through distinct molecular pathways compared to KRAS and HRAS.
• Targeting RAS signaling with inhibitors like farnesyltransferase inhibitors may be beneficial for autoimmune and lymphocyte homeostasis disorders.